The warnings and precautions of Brigatinib
Mar 6,2024
Introduction
ALUNBRIG (Brigatinib) is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Owing to the resistance associated with the first-generation (crizotinib) and second-generation (alectinib and ceritinib) ALK inhibitors, brigatinib was developed to achieve potent activity against a broad range of ALK resistance mutations. In preclinical studies, brigatinib showed higher potency and the capability to overcome mechanisms of resistance associated with crizotinib[1].
Warnings and precautions[2]
Interstitial Lung Disease (ILD)/Pneumonitis
Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients.
Hypertension
In ALTA 1L, hypertension was reported in 32% of patients receiving ALUNBRIG; 13% of patients experienced Grade 3 hypertension. In ALTA, hypertension was reported in 11% of patients in the 90 mg group and 21% of patients in the 90→180 mg group. Grade 3 hypertension occurred in 5.9% of patients overall. Control blood pressure prior to treatment with ALUNBRIG.
Bradycardia
In ALTA 1L, heart rates less than 50 beats per minute (bpm) occurred in 8.1% of patients receiving ALUNBRIG; one patient (0.7 %) experienced Grade 3 bradycardia. In ALTA, heart rates less than 50 beats per minute (bpm) occurred in 5.7% of patients in the 90 mg group and 7.6% in the 90→180 mg group. One patient (0.9%) in the 90 mg group experienced Grade 2 bradycardia. Monitor heart rate and blood pressure during treatment with ALUNBRIG.
Visual Disturbance
In ALTA 1L, Grade 1 or 2 adverse reactions leading to visual disturbance, including blurred vision, photophobia, photopsia, and reduced visual acuity, were reported in 7.4% of patients receiving ALUNBRIG. In ALTA, adverse reactions leading to visual disturbance, including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients treated with ALUNBRIG in the 90 mg group and 10% in the 90→180 mg group. Grade 3 macular edema and cataract occurred in one patient each in the 90→180 mg group.
Creatine Phosphokinase (CPK) Elevation
In ALTA 1L, creatine phosphokinase (CPK) elevation occurred in 81% of patients who received ALUNBRIG. The incidence of Grade 3 or 4 CPK elevation was 24%. Dose reduction for CPK elevation occurred in 15% of patients.
Pancreatic Enzyme Elevation
In ALTA 1L, amylase elevation occurred in 52% of patients, and Grade 3 or 4 amylase elevation occurred in 6.8% of patients who received ALUNBRIG. Lipase elevations occurred in 59% of patients, and Grade 3 or 4 lipase elevation occurred in 17%.
Hepatotoxicity
In ALTA 1L, aspartate aminotransferase (AST) elevations occurred in 72% of patients, and Grade 3 or 4 AST elevations occurred in 4.5% of patients who received ALUNBRIG. Alanine aminotransferase (ALT) elevations occurred in 52% of patients, and Grade 3 or 4 ALT elevations occurred in 5.2%.
The others include Hyperglycemia, Photosensitivity, and Embryo-Fetal Toxicity. Hence, Assess fasting serum glucose before initiation of ALUNBRIG and monitor periodically thereafter. Initiate or optimize anti-hyperglycemic medications as needed. There are no clinical data on the use of ALUNBRIG in pregnant women. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of ALUNBRIG.
References
[1] Neeraj Gupta. “Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.” Clinical Pharmacokinetics 62 8 (2023): 1063–1079.
- Related articles
- Related Qustion
- Brigatinib: Development History and Preclinical Studies Mar 18, 2024
Brigatinib, a crucial treatment for NSCLC patients with EGFR and ALK mutations, effectively inhibits ALK with unique features, overcoming resistance and offering hope in lung cancer treatment.
- Brigatinib: mechanism of action and pharmacokinetics and side effects Jul 12, 2023
Brigatinib is a small-molecule targeted therapy for advanced non-small cell lung cancer. Adverse events include nausea, diarrhea, fatigue, cough, interstitial lung disease, etc.
- Application and Pharmacology of Brigatinib Oct 14, 2019
Brigatinib (marketed as Alunbrig) is a small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.Brigatinib acts as both a anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
Fmoc-Phe-OH is a key compound in the field of peptide synthesis, playing an important role as a building block in the process of peptide assembly.....
Mar 6,2024APIMarbofloxacin is a synthetic fluoroquinolone veterinary-specific antimicrobial drug with broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria.....
Mar 6,2024DrugsBrigatinib
1197953-54-0You may like
- Brigatinib
-
- $0.00 / 1g
- 2024-08-20
- CAS:1197953-54-0
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Brigatinib
-
- $0.00 / 1kg
- 2024-08-19
- CAS:1197953-54-0
- Min. Order: 1kg
- Purity: 99.0%
- Supply Ability: 10000
- Brigatinib
-
- $0.00 / 1kg
- 2024-08-15
- CAS:1197953-54-0
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 20tons